These data confirmed the germline ATM and CHEK2 variants identified in tumour samples and identified two additional ATM variants plus one additional deleterious variant in each of BRCA2, CHEK2, and PALB2 (all heterozygous) (Table S3). This evidence concerns the gene BRCA2 and neoplasm.